Clinical research
Vaccinex announced topline data from the early manifest treatment arm of its Phase II SIGNAL trial of pepinemab in patients with early manifest and prodromal Huntington’s disease.
Genentech, a Roche company, presented data from three Phase III trials of Tecentriq (atezolizumab) in triple-negative breast cancer at the European Society for Medical Oncology Virtual Congress 2020 this weekend.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.
The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.
The overall survival benefit of Lynparza was shared this weekend, four months after the U.S. Food and Drug Administration approved it as a treatment for prostate cancer.
San Diego-based Mirati Therapeutics, a clinical-stage biotechnology company, is currently developing sitravatinib to address unmet medical needs in cancer care.
Biopharma companies focused on oncology continue to release data that will be presented at the 2020 virtual meeting of the European Society of Medical Oncology.
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
Regeneron and Sanofi broke new ground in treating advanced basal cell carcinoma with their anti-PD-1 inhibitor, Libtayo.
85% of participants in the trial of Actemra were from minority racial and ethnic groups, which are historically underrepresented in clinical studies.
PRESS RELEASES